NCT05592223View on ClinicalTrials.gov

Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 6, 2022

Primary Completion Date

August 23, 2023

Study Completion Date

December 1, 2023

Conditions
Tuberculosis
Interventions
DRUG

BCG Vaccine USP

2x10\^6 cfu Tice® BCG (ID)

DRUG

Isoniazid

INH in the dose of 300 mg for three days post BCG injection.

DRUG

Rifampin

RIF in the dose of 600 mg for seven days post BCG injection.

Trial Locations (1)

98109

Fred Hutchinson Cancer Center, Seattle

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER